TP53 and Thrombocytopenia: Small molecule inhibitors of MDM2 have shown anti-tumor efficacy in preclinical studies but disappointing results in clinical trials with many patients showing toxicities that were not seen in prior mouse studies, including hematological effects, such as thrombocytopenia leading to hemorrhage, and increased incidence of TP53 mutations with prolonged exposure35–37.